Navigation Links
Drug May Ease Cognitive Effects of Huntington's
Date:2/9/2010

Small study reports improvement in thinking skills,,

TUESDAY, Feb. 9 (HealthDay News) -- An experimental drug may improve thinking, learning and memory skills in people with Huntington's disease, an inherited neurodegenerative disorder, new research says.

Huntington's affects movement, behavior and cognitive abilities, and people with the disease usually die within 10 to 30 years of its onset. Cognitive problems begin early in the disease and increase as Huntington's progresses, leading to the inability to work or perform normal daily activities.

Currently, the only approved therapy for Huntington's is tetrabenazine, which treats movement problems but does not prevent cognitive decline or change the course of the disease.

In the new study, researchers assessed the safety and tolerability of a new drug with the proposed generic name latrepirdine, in people with mild to moderate Huntington's disease. The drug stabilizes and improves the function of mitochondria, parts of cells that help convert food into energy. Previous research has suggested that mitochondria abnormalities could play a role in Huntington's.

For 90 days, 46 people took 20 milligrams of latrepirdine three times a day, and 45 others took a placebo. The researchers said the drug was well-tolerated (87 percent of people taking latrepirdine completed the study, compared with 82 percent of the others), and the rates of adverse events were 70 percent in the treatment group, 80 percent in the placebo group.

The researchers also found that average scores on scales rating overall cognitive function improved in the treatment group and remained the same in the placebo group.

"Taken together, our data suggest that latrepirdine, at a dosage of 20 milligrams three times daily, is well-tolerated for 90 days in patients with Huntington's disease and may have a beneficial effect on cognition," wrote Dr. Karl Kieburtz, of the School of Medicine and Dentistry at the University of Rochester in New York, and his colleagues.

"Future studies of latrepirdine are planned to further evaluate the effect of latrepirdine on the cognitive and behavioral symptoms of Huntington's disease," they added.

The study is published in the February issue of Archives of Neurology.

More information

We Move has more about Huntington's disease.



-- Robert Preidt



SOURCE: JAMA/Archives journals, news release, Feb. 8, 2010


'/>"/>
Copyright©2010 ScoutNews,LLC.
All rights reserved

Related medicine news :

1. Hypertension may predict dementia in older adults with certain cognitive deficits
2. HAPPYneuron Launches the First Online Professional Destination for Clinical Cognitive Training.
3. New compound improves cognitive decline, symptoms of Alzheimers disease in rodents
4. First Global, Virtual Summit on Cognitive Health and Performance Features 200 Sharp Brains
5. Expert Panel Reaches Consensus on Our Ability to Improve Cognitive Health
6. Study finds significantly worse outcomes in cancer patients with cognitive impairment
7. Caffeine doesnt reverse the negative cognitive impact of alcohol, study shows
8. Univalor and Cognitive Sensing Inc. to commercialize 4 University of Montreal discoveries
9. Alzheimer's Foundation of America Applauds Inclusion of Cognitive Impairment Detection in Healthcare Reform
10. Diet, Cognitive Ability May Play Role in Heart Disease
11. HAPPYneuron Launches Beta Program for Innovative Cognitive Rehab Tools at AMIA Conference in San Francisco
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/27/2017)... ... February 27, 2017 , ... Sunshine Coast Health Centre (SCHC), ... Canada, at https://www.sunshinecoasthealthcentre.ca/ , is proud to announce the addition of a ... the Centre's commitment to innovation in drug rehab and alcohol treatment strategies beyond ...
(Date:2/27/2017)... ... February 27, 2017 , ... New Jersey ranks among ... all types and genders. And the need for advanced services is growing. , ... top-rated cancer care program, in collaboration with their non-profit partners in their fight against ...
(Date:2/26/2017)... Ireland (PRWEB) , ... February 26, 2017 , ... ... as in 2011 the lab became the world’s first to be ISO/IEC 17025:2005 ... 1 (cat allergen) analysis. , ISO/IEC 17025:2005 is the globally recognised standard that ...
(Date:2/26/2017)... ... February 26, 2017 , ... IndustryArchive.Org . is announcing ... B2B Marketing. B2B Sellers will now only pay for B.A.N.T. quality sales leads based ... of IndustryArchive.Org, said, “Given the new reality that B2B buyers are controlling the sales ...
(Date:2/26/2017)... (PRWEB) , ... February 26, 2017 , ... ... patients after receiving cognitive rehabilitation, according to a study released today at the ... that cognitive rehabilitation programs are proven to be effective in improving cognitive function ...
Breaking Medicine News(10 mins):
(Date:2/27/2017)... , February 27, 2017 A recent research ... medical marijuana market alone is expected to reach a value of ... along with 28 states have legalized marijuana for medical ... Florida , North Dakota , ... were approved to use the drug in medical applications such as ...
(Date:2/27/2017)... SEATTLE , Feb. 27, 2017  CTI BioPharma Corp. ... of Adam Craig , M.D., Ph.D., as President and ... Directors effective March 20, 2017. Dr. Craig succeeds Richard ... serve on the company,s Board of Directors.  Dr. Craig has ... development in both the US and Europe ...
(Date:2/27/2017)... 27, 2017 Period October – December 2016 ... result amounted to SEK -16.4 (-6.4) million Result after tax ... before and after dilution Cash flow from operating activities amounted ... ... (0.4) million Operating result amounted to SEK -39.5 (-29.5) million ...
Breaking Medicine Technology: